| Methods |
Randomised, placebo‐controlled, double‐blind cross‐over |
| Participants |
16 participants (13 CPEO, 3 myopathy) |
| Interventions |
Creatine monohydrate 20 g /day or placebo for 4 weeks. Washout ≥ 24 days in all participants |
| Outcomes |
Visual analogue scales of subjective weakness and general activity, neuromuscular symptom score, function time test, function ranking test, ataxia score, muscle strength, motor ability score. Resting and post‐exercise lactate, maximal voluntary muscle torque, aerobic exercise performance, eye motility and eyelid drooping |
| Notes |
No effect |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Method of randomisation not specified |
| Allocation concealment (selection bias) |
Unclear risk |
Method of allocation not specified |
| Incomplete outcome data (attrition bias)
All outcomes |
Low risk |
All participants completed all outcome assessments |
| Selective reporting (reporting bias) |
Low risk |
All outcome measures in methods section were reported in results section |
| Other bias |
Low risk |
None identified |
| Blinding of participants and personnel (performance bias)
All outcomes |
Low risk |
"double‐blind, placebo‐controlled 2x2 crossover trial" |
| Blinding of outcome assessment (detection bias)
All outcomes |
Low risk |
Participants were randomly assigned to start in either the creatine or placebo arm |
